{"title":"根据药代动力学数据调整美西汀的剂量。","authors":"M Bogaert","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Although pharmacodynamic factors are very important in regard to the need for dose adaptation of mexiletine, pharmacokinetic factors also play a role. Pharmacokinetic variability for mexiletine is mainly due to interindividual differences in biotransformation rate in patients with normal hepatic function. Whether the existence of a compromised renal, hepatic or cardiac function alters dosage requirements is not clear. Oral administration of three times 250 mg daily is probably a good starting dose but adaptation will be necessary in many patients. The need for a loading dose depends on the urgency of the situation. For the intravenous administration a loading dose is always necessary. A regimen consisting of 100 to 250 mg mexiletine over 10 minutes, followed by 200 mg over 1 hour has been proposed. This is then followed by a continuous infusion of 0.5-2.5 mg/min. Pharmacodynamic variations notwithstanding, it is of interest to obtain plasma levels of mexiletine within the range of 1-2 microgram/ml.</p>","PeriodicalId":75374,"journal":{"name":"Acta cardiologica. Supplementum","volume":" 25","pages":"67-73"},"PeriodicalIF":0.0000,"publicationDate":"1980-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adaptation of the dose of mexiletine according to pharmacokinetic data.\",\"authors\":\"M Bogaert\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Although pharmacodynamic factors are very important in regard to the need for dose adaptation of mexiletine, pharmacokinetic factors also play a role. Pharmacokinetic variability for mexiletine is mainly due to interindividual differences in biotransformation rate in patients with normal hepatic function. Whether the existence of a compromised renal, hepatic or cardiac function alters dosage requirements is not clear. Oral administration of three times 250 mg daily is probably a good starting dose but adaptation will be necessary in many patients. The need for a loading dose depends on the urgency of the situation. For the intravenous administration a loading dose is always necessary. A regimen consisting of 100 to 250 mg mexiletine over 10 minutes, followed by 200 mg over 1 hour has been proposed. This is then followed by a continuous infusion of 0.5-2.5 mg/min. Pharmacodynamic variations notwithstanding, it is of interest to obtain plasma levels of mexiletine within the range of 1-2 microgram/ml.</p>\",\"PeriodicalId\":75374,\"journal\":{\"name\":\"Acta cardiologica. Supplementum\",\"volume\":\" 25\",\"pages\":\"67-73\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1980-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta cardiologica. Supplementum\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta cardiologica. Supplementum","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Adaptation of the dose of mexiletine according to pharmacokinetic data.
Although pharmacodynamic factors are very important in regard to the need for dose adaptation of mexiletine, pharmacokinetic factors also play a role. Pharmacokinetic variability for mexiletine is mainly due to interindividual differences in biotransformation rate in patients with normal hepatic function. Whether the existence of a compromised renal, hepatic or cardiac function alters dosage requirements is not clear. Oral administration of three times 250 mg daily is probably a good starting dose but adaptation will be necessary in many patients. The need for a loading dose depends on the urgency of the situation. For the intravenous administration a loading dose is always necessary. A regimen consisting of 100 to 250 mg mexiletine over 10 minutes, followed by 200 mg over 1 hour has been proposed. This is then followed by a continuous infusion of 0.5-2.5 mg/min. Pharmacodynamic variations notwithstanding, it is of interest to obtain plasma levels of mexiletine within the range of 1-2 microgram/ml.